These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 25900274)
21. Long-term impairment of the lacrimal glands after radioiodine therapy: a cross-sectional study. Zettinig G; Hanselmayer G; Fueger BJ; Hofmann A; Pirich C; Nepp J; Dudczak R Eur J Nucl Med Mol Imaging; 2002 Nov; 29(11):1428-32. PubMed ID: 12397459 [TBL] [Abstract][Full Text] [Related]
22. Association between radioiodine treatment for thyroid cancer and risk of stroke. Lin CY; Lin CL; Lo YC; Kao CH Head Neck; 2017 Nov; 39(11):2311-2318. PubMed ID: 28815788 [TBL] [Abstract][Full Text] [Related]
23. Radiotherapy for primary thyroid cancer as a risk factor for second primary cancers. Chuang SC; Hashibe M; Yu GP; Le AD; Cao W; Hurwitz EL; Rao JY; Neugut AI; Zhang ZF Cancer Lett; 2006 Jul; 238(1):42-52. PubMed ID: 16039041 [TBL] [Abstract][Full Text] [Related]
24. Epiphora after radioactive iodine therapy in a low-risk patient. Song H; Jeong J; Ju Koh M Clin Nucl Med; 2015 Jun; 40(6):536-7. PubMed ID: 25674875 [TBL] [Abstract][Full Text] [Related]
25. Increased Risk of Leukemia After Radioactive Iodine Therapy in Patients with Thyroid Cancer: A Nationwide, Population-Based Study in Korea. Seo GH; Cho YY; Chung JH; Kim SW Thyroid; 2015 Aug; 25(8):927-34. PubMed ID: 26133388 [TBL] [Abstract][Full Text] [Related]
26. [Quantitative salivary gland scintigraphy--a recommended examination prior to and after radioiodine therapy]. Bohuslavizki KH; Brenner W; Lassmann S; Tinnemeyer S; Kalina S; Clausen M; Henze E Nuklearmedizin; 1997 Apr; 36(3):103-9. PubMed ID: 9162904 [TBL] [Abstract][Full Text] [Related]
27. The biodistribution of radioiodine on posttherapy iodine-131 scans in thyroid cancer patients with chronic renal failure. Aktaş A; Kavak K; Kocabaş B; Aras M; Tütüncü NB; Gençoğlu A Nucl Med Commun; 2008 Nov; 29(11):943-8. PubMed ID: 18836371 [TBL] [Abstract][Full Text] [Related]
28. Effect of selenium supplementation for protection of salivary glands from iodine-131 radiation damage in patients with differentiated thyroid cancer. Son H; Lee SM; Yoon RG; Lee H; Lee I; Kim S; Chung WY; Lee JW Hell J Nucl Med; 2017; 20(1):62-70. PubMed ID: 28315910 [TBL] [Abstract][Full Text] [Related]
29. Increased risk of certain second primary malignancies in patients treated for well-differentiated thyroid cancer. Hakala TT; Sand JA; Jukkola A; Huhtala HS; Metso S; Kellokumpu-Lehtinen PL Int J Clin Oncol; 2016 Apr; 21(2):231-239. PubMed ID: 26410770 [TBL] [Abstract][Full Text] [Related]
30. Iodine kinetics and dosimetry in the salivary glands during repeated courses of radioiodine therapy for thyroid cancer. Liu B; Huang R; Kuang A; Zhao Z; Zeng Y; Wang J; Tian R Med Phys; 2011 Oct; 38(10):5412-9. PubMed ID: 21992360 [TBL] [Abstract][Full Text] [Related]
31. Association Between 131I Treatment for Thyroid Cancer and Risk of Receiving Cataract Surgery: A Cohort Study from Taiwan. Lin CM; Yeh PT; Doyle P; Tsan YT; Chen PC; J Nucl Med; 2016 Jun; 57(6):836-41. PubMed ID: 26837336 [TBL] [Abstract][Full Text] [Related]
32. Salivary gland dysfunction after radioactive iodine (I-131) therapy in patients following total thyroidectomy: emphasis on radioactive iodine therapy dose. Lee HN; An JY; Lee KM; Kim EJ; Choi WS; Kim DY Clin Imaging; 2015; 39(3):396-400. PubMed ID: 25630229 [TBL] [Abstract][Full Text] [Related]
33. Incidence of second primary malignancies during a long-term surveillance of patients with differentiated thyroid carcinoma in relation to radioiodine treatment. Fallahi B; Adabi K; Majidi M; Fard-Esfahani A; Heshmat R; Larijani B; Haghpanah V Clin Nucl Med; 2011 Apr; 36(4):277-82. PubMed ID: 21368600 [TBL] [Abstract][Full Text] [Related]
34. Lacrimal System Obstruction After Radioiodine Therapy in Differentiated Thyroid Carcinomas: A Prospective Comparative Study. da Fonseca FL; Yamanaka PK; Kato JM; Matayoshi S Thyroid; 2016 Dec; 26(12):1761-1767. PubMed ID: 27565021 [TBL] [Abstract][Full Text] [Related]
35. Risk of second primary cancer following differentiated thyroid cancer. Berthe E; Henry-Amar M; Michels JJ; Rame JP; Berthet P; Babin E; Icard P; Samama G; Galateau-Sallé F; Mahoudeau J; Bardet S Eur J Nucl Med Mol Imaging; 2004 May; 31(5):685-91. PubMed ID: 14747959 [TBL] [Abstract][Full Text] [Related]
36. Incidence of second malignancies in prostate cancer patients treated with low-dose-rate brachytherapy and radical prostatectomy. Hamilton SN; Tyldesley S; Hamm J; Jiang WN; Keyes M; Pickles T; Lapointe V; Kahnamelli A; McKenzie M; Miller S; Morris WJ Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):934-41. PubMed ID: 25240272 [TBL] [Abstract][Full Text] [Related]
37. Salivary gland scintigraphy after radioiodine therapy. Malpani BL; Samuel AM; Jaiswar RK Nucl Med Commun; 1998 Feb; 19(2):183-4. PubMed ID: 9548203 [No Abstract] [Full Text] [Related]
38. Does vitamin E protect salivary glands from I-131 radiation damage in patients with thyroid cancer? Fallahi B; Beiki D; Abedi SM; Saghari M; Fard-Esfahani A; Akhzari F; Mokarami B; Eftekhari M Nucl Med Commun; 2013 Aug; 34(8):777-86. PubMed ID: 23708871 [TBL] [Abstract][Full Text] [Related]
39. Blood dosimetry and dose-rate effects after radioiodine therapy of differentiated thyroid cancer. Lassmann M; Luster M; Hänscheid H; Reiners C J Nucl Med; 2005 May; 46(5):899. PubMed ID: 15872368 [No Abstract] [Full Text] [Related]
40. Second primary malignancies in thyroid cancer patients. Rubino C; de Vathaire F; Dottorini ME; Hall P; Schvartz C; Couette JE; Dondon MG; Abbas MT; Langlois C; Schlumberger M Br J Cancer; 2003 Nov; 89(9):1638-44. PubMed ID: 14583762 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]